Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
|
|
Phio Pharmaceuticals Corp. (RXII)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Bitterman Robert J (President & CEO) has filed a Form 4 on Phio Pharmaceuticals Corp.|
Txns:
| Paid exercise price by delivering 917 shares
@ $1.51, valued at
$1.4k
|
|
| 08/21/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update MARLBOROUGH, Mass., August 10, 2023—Phio Pharmaceuticals Corp. , a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2023 and provided a business update. “Following FDA clearance of our IND for PH-762, we are moving forward with plans for a clinical trial for stages one, two and four of cutaneous squamous cell , stage four melanoma and Merkel cell,” said Robert Bitterman, President and CEO. The initial multi-center, dose-escalating, Phase 1b clinical trial is designed to evaluate the safety and tolerability of neo..." |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Bitterman Robert J (President & CEO) has filed a Form 4 on Phio Pharmaceuticals Corp.|
Txns:
| Bought 1,000 shares
@ $2.88, valued at
$2.9k
Bought 1,000 shares
@ $2.84, valued at
$2.8k
|
|
| 06/15/2023 |
4
| Ferrara Robert L (Director) has filed a Form 4 on Phio Pharmaceuticals Corp.|
Txns:
| Bought 2,000 shares
@ $3.1, valued at
$6.2k
|
|
| 06/09/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 06/09/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/09/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/08/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 06/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"FORM OF SERIES A COMMON STOCK WARRANT",
"FORM OF SERIES B COMMON STOCK WARRANT",
"FORM OF PRE-FUNDED COMMON STOCK WARRANT",
"LEGAL OPINION",
"FORM OF SECURITIES PURCHASE AGREEMENT (RDO)",
"FORM OF SECURITIES PURCHASE AGREEMENT (PIPE)",
"FORM OF REGISTRATION RIGHTS AGREEMENT",
"Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules MARLBOROUGH, Mass., May 31, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. , a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 233,646 of its shares of common stock at a purchase price of $4.28 per share in a registered direct offering. In a concurrent private placement, Phio has also agreed to issue and sell an aggregate of 700,935 of its shares of common stock , at the same purchase price of $4.28 per share as in the registe...",
"Public Relations Contact" |
|
| 06/01/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/16/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"PHIO PHARMACEUTICALS CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 2,134 $ 1,586 General and administrative 1,468 1,054 Total operating expenses 3,602 2,640 Operating loss Total other expense, net – Net loss $ $ Net loss per common share: Basic and diluted $ $ Weighted average number of common shares outstanding: Basic and diluted 1,142,213 1,130,344 4 PHIO PHARMACEUTICALS CORP. CONDENSED CONSOLIDATED BALANCE SHEETS" |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/02/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 04/28/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"PHIO PHARMACEUTICALS CORP. CONSOLIDATED STATEMENTS OF OPERATIONS Year Ended December 31, 2022 2021 Operating expenses: Research and development $ 7,012 $ 8,886 General and administrative 4,450 4,625 Total operating expenses 11,462 13,511 Operating loss Total other income, net 224 Net loss $ $ Net loss per common share: Basic $ $ Diluted $ $ Weighted average number of common shares outstanding Basic 1,136,566 1,069,234 Diluted 1,136,566 1,069,234 4 PHIO PHARMACEUTICALS CORP. CONSOLIDATED BALANCE SHEETS" |
|
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
|
|
|